https://www.selleckchem.com/pr....oducts/abtl-0812.htm
We suggest that an siRNA-LNP therapeutic approach could prove highly useful in treating COVID-19 disease as an adjunctive therapy to current vaccine strategies.Although anti-tumor immunity through checkpoint inhibitors, specifically anti PD-1/PD-L1 interaction, is a promising approach for cancer therapy. However, early clinical trials indicate that colorectal cancer (CRC) do not respond well to immune checkpoint therapies, new effective immunotherapy approaches to CRC warrant further study. Simvastatin is an inhibitor of 3-hydroxy-3-m
Curtir
Comentario
Compartilhar
